Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200044 | 0.83 | MAPK1 (0.64) | MAPK1SMN1; SMN2KDM1ASIGMAR1L3MBTL1 | |
| SCHEMBL14430489 | 0.81 | MAPK1 (0.61) | MAPK1SMN1; SMN2KDM1ASIGMAR1L3MBTL1 | |
| SCHEMBL14430479 | 0.78 | MAPK1 (0.61) | MAPK1SMN1; SMN2KDM1ASIGMAR1L3MBTL1 | |
| SCHEMBL5198166 | 0.75 | MAPK1 (0.59) | MAPK1SMN1; SMN2SIGMAR1L3MBTL1CHRM2 | |
| SCHEMBL14430366 | 0.72 | L3MBTL1 (0.45) | MAPK1SMN1; SMN2KDM1AL3MBTL1CHRM4 | |
| SCHEMBL7809995 | 0.70 | MAPK1 (0.60) | MAPK1SMN1; SMN2KDM1ASIGMAR1L3MBTL1 | |
| SCHEMBL14430497 | 0.70 | MAPK1 (0.56) | MAPK1SMN1; SMN2KDM1ASIGMAR1L3MBTL1 | |
| SCHEMBL28710237 | 0.69 | SIGMAR1 (0.42) | KDM1ASIGMAR1EBP | |
| SCHEMBL14430492 | 0.69 | MAPK1 (0.44) | MAPK1SMN1; SMN2KDM1ASIGMAR1 | |
| SCHEMBL13921299 | 0.68 | MAPK1 (0.82) | MAPK1SMN1; SMN2SIGMAR1L3MBTL1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | GRIN1, PARK7, GRIN3A | MAPK1 664/4885SMN1; SMN2 46/4885KDM1A 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.